Compugen to Present New Research Enabling Accurate Detection and Study of Novel Target PVRIG at AACR 2023
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...